These highlights do not include all the information needed to use Gonal-f ® RFF* Redi-ject™ safely and effectively. See full prescribing information for Gonal-f ® RFF Redi-ject™
			Gonal-f ® RFF* Redi-ject™ (follitropin alfa injection) for subcutaneous use
			*revised formulation female
			Initial U.S. Approval: 1997
			RECENT MAJOR CHANGES
		
			
				
					
						
						
					
					
						
							| Dosage and Administration |  | 
						
							| Redi-ject™ auto-injection device (2.1) | 10/13 | 
						
							| Contraindications (4) | 10/13 | 
						
							| Warnings and Precautions |  | 
						
							| Hypersensitivity Reactions and Anaphylaxis (5.1) | 10/13 | 
						
							| Ovarian Hyperstimulation Syndrome (OHSS) (5.3) | 10/13 | 
						
							| Pulmonary and Vascular Complications (5.4) | 10/13 | 
						
							| Ovarian Torsion (5.5) | 10/13 | 
						
							| Multi-fetal Gestation and Birth (5.6) | 10/13 | 
						
							| Congenital Malformations (5.7) | 10/13 | 
						
							| Ectopic Pregnancy (5.8) | 10/13 | 
						
							| Spontaneous Abortion (5.9) | 10/13 | 
						
							| Ovarian Neoplasms (5.10) | 10/13 | 
					
				
			 
		 
		
			INDICATIONS AND USAGE
		
			
				
					Gonal-f® RFF Redi-ject™ is a prefilled gonadotropin-containing auto-injection device indicated for:
				
					- 
						Induction of ovulation and pregnancy in oligo-anovulatory women in whom the cause of infertility is functional and not due to primary ovarian failure (1.1)
- 
						Development of multiple follicles in ovulatory women as part of an Assisted Reproductive Technology (ART) cycle (1.2)
 
			
				DOSAGE AND ADMINISTRATION
		 
		
			
				
					Ovulation Induction (2.2)
				
					- 
						Initial starting dose of the first cycle - 75 International Units of Gonal-f® RFF Redi-ject™ per day for 14 days, administered subcutaneously
- 
						Individualization doses after 14 days
- 
						Doses larger than 300 International Units of FSH per day are not recommended
					Assisted Reproductive Technology (2.3)
				
					- 
						Initial starting dose of the first cycle - 150 International Units per day, administered subcutaneously
- 
						Dosage adjustments after 3-5 days and by 75-150 International Units at each adjustment
- 
						Do not administer doses greater than 450 International Units per day
 
			
				DOSAGE FORMS AND STRENGTHS
		 
		
			
				- 
					Injection: Gonal-f® RFF Redi-ject™ 300 International Units per 0.5 mL in prefilled, multiple dose disposable delivery system (3)
- 
					Injection: Gonal-f® RFF Redi-ject&tr